1. Home
  2. IDYA vs VTMX Comparison

IDYA vs VTMX Comparison

Compare IDYA & VTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IDYA
  • VTMX
  • Stock Information
  • Founded
  • IDYA 2015
  • VTMX 1998
  • Country
  • IDYA United States
  • VTMX Mexico
  • Employees
  • IDYA N/A
  • VTMX N/A
  • Industry
  • IDYA Biotechnology: Pharmaceutical Preparations
  • VTMX
  • Sector
  • IDYA Health Care
  • VTMX
  • Exchange
  • IDYA Nasdaq
  • VTMX Nasdaq
  • Market Cap
  • IDYA 1.9B
  • VTMX 2.3B
  • IPO Year
  • IDYA 2019
  • VTMX 2023
  • Fundamental
  • Price
  • IDYA $21.23
  • VTMX $27.35
  • Analyst Decision
  • IDYA Strong Buy
  • VTMX Sell
  • Analyst Count
  • IDYA 13
  • VTMX 2
  • Target Price
  • IDYA $53.42
  • VTMX $29.00
  • AVG Volume (30 Days)
  • IDYA 1.1M
  • VTMX 155.6K
  • Earning Date
  • IDYA 08-05-2025
  • VTMX 07-24-2025
  • Dividend Yield
  • IDYA N/A
  • VTMX 2.34%
  • EPS Growth
  • IDYA N/A
  • VTMX N/A
  • EPS
  • IDYA N/A
  • VTMX 0.13
  • Revenue
  • IDYA $7,000,000.00
  • VTMX $258,927,122.00
  • Revenue This Year
  • IDYA $101.20
  • VTMX $17.35
  • Revenue Next Year
  • IDYA $286.70
  • VTMX $11.82
  • P/E Ratio
  • IDYA N/A
  • VTMX $20.36
  • Revenue Growth
  • IDYA N/A
  • VTMX 15.06
  • 52 Week Low
  • IDYA $13.45
  • VTMX $21.30
  • 52 Week High
  • IDYA $44.42
  • VTMX $32.84
  • Technical
  • Relative Strength Index (RSI)
  • IDYA 62.23
  • VTMX 44.59
  • Support Level
  • IDYA $21.08
  • VTMX $26.71
  • Resistance Level
  • IDYA $22.37
  • VTMX $27.37
  • Average True Range (ATR)
  • IDYA 0.92
  • VTMX 0.51
  • MACD
  • IDYA -0.09
  • VTMX -0.16
  • Stochastic Oscillator
  • IDYA 61.72
  • VTMX 30.21

About IDYA IDEAYA Biosciences Inc.

IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.

About VTMX Corporacion Inmobiliaria Vesta S.A.B de C.V. each representing ten (10)

Corporacion Inmobiliaria Vesta SAB de CV is an internally managed real estate company that owns, manages, develops, and leases industrial properties in Mexico. The Company's primary business is the acquisition, development, and management of industrial and distribution center real estate. The company designs and constructs park-to-suit projects across various industries; undertakes build-to-suit projects; and provides site selection, design and engineering, and sale and leaseback services. The primary source of revenue is the rental income received from customers under operating leases. It serves aerospace, automotive, food and beverage, logistics, medical devices, plastics, and other industries.

Share on Social Networks: